Imara reports Q3 net loss $13.6M; tovinontrine Phase 2b interim data expected Q4 2021

Enliven Therapeutics, Inc.

2022-Q3 EPS reported -$1.33

Net loss $13.6M ($0.55/share) vs $12.4M ($0.72/share) in Q3 2020; cash & investments $102.8M.
R&D expenses $10.4M; FY2021 R&D guidance $40-45M, G&A $12-13M; cash runway into Q1 2023.
Phase 2b Ardent (SCD) and Forte (beta-thalassemia) trials fully enrolled; interim data Q4 2021, primary analysis Q1 2022.
New pipeline asset IMR-261 (Nrf2 activator) acquired; preclinical data to be presented at ASH 2021.
Hired cardiologist Dr. Toni Bransford to lead HFpEF Phase 2 trial of tovinontrine; trial expected to start 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.